Explanipedia

In Vivo Determinants of Hepatitis C Virus Adaptation and Escape From Neutralizing Antibody AR5A Open

Rodrigo Velázquez‐Moctezuma, Rani Burm, Lieven Verhoye, Laura Collignon, Kenn Holmbeck , et al. · 2025

We show that L665S is an AR5A escape mutation in vivo, supporting the use of cost-effective vaccine escape studies in vitro. We also identify novel in vivo adaptive mutations and characterize their mechanism of action, thus facilitating in…

A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses Open

Roxanne Fouillé, Éloi R. Verrier, Amse De Meyer, Lieven Verhoye, Maud Michelet , et al. · 2025

Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice Open

George Ssebyatika, Katja Dinkelborg, L.J. Stroh, Florian Hinte, Laura Corneillie , et al. · 2025

Hepatitis E virus (HEV) causes 3.3 million symptomatic cases and 44,000 deaths per year. Chronic infections can arise in immunocompromised individuals, and pregnant women may suffer from fulminant disease as a consequence of HEV infection.…

Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells Open

Cong Si Tran, Julia Kersten, Jingyi Yan, Marco Breinig, Thorben Huth , et al. · 2024

PI4KIIIα regulates cytoskeleton organization via PIK3C2γ/Akt2/paxillin-cofilin to favor migration and invasion of liver cancer cells. These findings provide mechanistic insight into the contribution of PI4KIIIα and HCV to the progression o…

Phosphatidylinositol 4-kinase III alpha governs cytoskeletal organization for invasiveness of liver cancer cells Open

Cong Si Tran, Julia Kersten, Marco Breinig, Jingyi Yan, Tanja Poth , et al. · 2023

Background and Aims High expression of phosphatidylinositol 4-kinase III alpha (PI4KIIIα) correlates with poor survival rates in patients with hepatocellular carcinoma (HCC). In addition, Hepatitis C virus (HCV) infections activate PI4KIII…

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection Open

Rani Burm, Freya Van Houtte, Lieven Verhoye, Ahmed Atef Mesalam, Sandra Ciesek , et al. · 2022

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections Open

Rani Burm, Panagiota Maravelia, Gustaf Ahlén, Sandra Ciesek, Noelia Caro Pérez , et al. · 2022

Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and rai…

A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function Open

Toni Luise Meister, Yannick Brüggemann, Maximilian K. Nocke, Rainer G. Ulrich, Jonas Schuhenn , et al. · 2022

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and is the leading cause of enterically transmitted viral hepatitis worldwide. Ribavirin (RBV) is currently the only treatment option for many patients; however, cases…

Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems Open

Thomas Burkard, Nora Proske, Kathrin Resner, Laura Collignon, Leonard Knegendorf , et al. · 2022

Background: Hepatitis C virus (HCV) constitutes a global health problem, while hepatitis E virus (HEV) is the major cause of acute viral hepatitis globally. HCV/HEV co-infections have been poorly characterized, as they are hampered by the …

Study of Hepatitis E Virus-4 Infection in Human Liver-Chimeric, Immunodeficient, and Immunocompetent Mice Open

Laura Collignon, Lieven Verhoye, Renate Hakze‐van der Honing, Wim H. M. van der Poel, Philip Meuleman · 2022

The hepatitis E virus (HEV) is responsible for 20 million infections worldwide per year. Although, HEV infection is mostly self-limiting, immunocompromised individuals may evolve toward chronicity. The lack of an efficient small animal mod…

A Role for B Cells to Transmit Hepatitis C Virus Infection Open

Isabelle Desombere, Freya Van Houtte, Ali Farhoudi, Lieven Verhoye, Caroline Buysschaert , et al. · 2021

Hepatitis C virus (HCV) is highly variable and transmits through infected blood to establish a chronic liver infection in the majority of patients. Our knowledge on the infectivity of clinical HCV strains is hampered by the lack of in vitr…

Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice Open

Richard J. P. Brown, Birthe Tegtmeyer, Julie Sheldon, Tanvi Khera, Anggakusuma , et al. · 2020

Two transmembrane proteins cooperate to block infection of murine hepatocytes by human-tropic hepatitis C virus.

A role for B cells to transmit hepatitis C virus infection Open

Isabelle Desombere, Freya Van Houtte, Ali Farhoudi, Lieven Verhoye, Caroline Buysschaert , et al. · 2020

Hepatitis C virus (HCV) is highly variable and transmits through infected blood to establish a chronic liver infection in the majority of patients. Our knowledge of the infectivity of clinical HCV strains is hampered by the lack of in vitr…

Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells Open

Joery De Kock, Robim M. Rodrigues, Steven Branson, Lieven Verhoye, Haaike Colemonts‐Vroninks , et al. · 2020

Human skin-derived precursors (SKP) represent a group of somatic stem/precursor cells that reside in dermal skin throughout life that harbor clinical potential. SKP have a high self-renewal capacity, the ability to differentiate into multi…

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections Open

Panagiota Maravelia, Lars Frelin, Yi Ni, Noelia Caro Pérez, Gustaf Ahlén , et al. · 2020

Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes Open

Eleftherios Michailidis, Koen Vercauteren, Liliana Mâncio-Silva, Linda Andrus, Cyprien Jahan , et al. · 2020

Primary human hepatocytes (PHHs) are an essential tool for modeling drug metabolism and liver disease. However, variable plating efficiencies, short lifespan in culture, and resistance to genetic manipulation have limited their use. Here, …

Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes Open

Eleftherios Michailidis, Koen Vercauteren, Liliana Mâncio-Silva, Linda Andrus, Cyprien Jahan , et al. · 2020

© 2020 National Academy of Sciences. All rights reserved. Primary human hepatocytes (PHHs) are an essential tool for modeling drug metabolism and liver disease. However, variable plating efficiencies, short lifespan in culture, and resista…

Robust hepatitis E virus infection and transcriptional response in human hepatocytes Open

Daniel Tödt, Martina Friesland, Nora Moeller, Dimas Praditya, Volker Kinast , et al. · 2020

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and the leading cause for acute viral hepatitis worldwide. The virus is classified as a member of the genus Orthohepevirus A within the Hepeviridae family. Due to the …

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis Open

Ibrahim M. Sayed, Lieven Verhoye, Claire Montpellier, Florence Abravanel, Jacques Izopet , et al. · 2019

Background Hepatitis E virus infection (HEV) is an emerging problem in developed countries. Diagnosis of HEV infection is based on the detection of HEV-specific antibodies, viral RNA, and/or antigen (Ag). Humanized mice were previously rep…

The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo Open

Daniel Tödt, Nora Moeller, Dimas Praditya, Volker Kinast, Martina Friesland , et al. · 2018

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genus Orthohepevirus in the family Hepeviridae. HEV infections are the common cause of acute hepatitis but can also take chronic courses. Ribavirin…

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1 Open

Ahmed Atef Mesalam, Isabelle Desombere, Ali Farhoudi, Freya Van Houtte, Lieven Verhoye , et al. · 2017

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo Open

Isabelle Desombere, Ahmed Atef Mesalam, Richard A. Urbanowicz, Freya Van Houtte, Lieven Verhoye , et al. · 2017

Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy Open

Tanvi Khera, Daniel Tödt, Koen Vercauteren, C. Patrick McClure, Lieven Verhoye , et al. · 2017

Development and characterization of a human monoclonal antibody for prevention of HCV recurrence in liver transplant patients Open

Ahmed Atef Mesalam, Isabelle Desombere, Richard A. Urbanowicz, Daniel X. Johansson, Koen Vercauteren , et al. · 2017

More than 170 million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver transplantation is the only option for patients with H…

Impact of HEV infection on the human hepatic innate immune response in human liver chimeric mice Open

Ibrahim Mahmoud Sayed Ibrahim, Lieven Verhoye, Lander Foquet, Florence Abravanel, Aliasghar Farhoudi Moghadam , et al. · 2017

Table of contents Open

Ekihiro Seki, Philippe Gual, Catherine Postic, Tamar H. Taddei, Humberto Reyes , et al. · 2016

Page 1325) show that hepatic stellate cells integrate signals from Kupffer and sinusoidal endothelial cells to mediate inflammatory damage to hepatocytes.Activation of DP1 prostaglandin receptors on the stellate cells with BW245C inhibits …

Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge Open

Isabelle Desombere, Samira Fafi–Kremer, Freya Van Houtte, Patrick Pessaux, Ali Farhoudi , et al. · 2015

End‐stage liver disease (ESLD) caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation, the liver graft of viremic patients universally becomes infected by cir…

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice Open

Jannick Prentoe, Lieven Verhoye, Rodrigo Velázquez‐Moctezuma, Caroline Buysschaert, Ali Farhoudi , et al. · 2015

Objective HCV is a major cause of chronic liver disease worldwide, but the role of neutralising antibodies (nAbs) in its natural history remains poorly defined. We analysed the in vivo role of hypervariable region 1 (HVR1) for HCV virion p…

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice Open

Koen Vercauteren, Richard J. P. Brown, Ahmed Atef Mesalam, Juliane Doerrbecker, Sabin Bhuju , et al. · 2015

This study provides preclinical in vivo evidence that addition of an entry inhibitor to an anti-HCV DAA regimen restricts the breakthrough of DAA-resistant viruses. Our approach is an excellent strategy to prevent therapeutic failure cause…

Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model Open

Lander Foquet, Cornelus C. Hermsen, Lieven Verhoye, Geert‐Jan van Gemert, Riccardo Cortese , et al. · 2015

Objectives Plasmodium falciparum sporozoites, deposited in the skin by infected Anopheles mosquitoes taking a blood meal, cross the endothelium of skin capillaries and travel to the liver where they traverse Kupffer cells and hepatocytes t…

Lieven Verhoye YOU? Author Swipe